Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival
Dinesh S. Rao, … , Martin G. Sanda, Theodora S. Ross
Dinesh S. Rao, … , Martin G. Sanda, Theodora S. Ross
Published August 1, 2002
Citation Information: J Clin Invest. 2002;110(3):351-360. https://doi.org/10.1172/JCI15529.
View: Text | PDF
Article Development

Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival

  • Text
  • PDF
Abstract

Research Article

Authors

Dinesh S. Rao, Teresa S. Hyun, Priti D. Kumar, Ikuko F. Mizukami, Mark A. Rubin, Peter C. Lucas, Martin G. Sanda, Theodora S. Ross

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Full-length HIP1 is overexpressed specifically in tumor tissue from TRAM...
Full-length HIP1 is overexpressed specifically in tumor tissue from TRAMP mice and is not proapoptotic. (a) Western blot analysis of normal and prostate cancer tissue from a mouse model of prostate cancer, TRAMP. Normal and prostate cancer tissue was immunoblotted using mAb’s to HIP1, clathrin heavy chain (clathrin), and adaptin-γ, a subunit of the clathrin-associated adaptor protein AP1. nl, normal prostate. (b) A mutant of HIP1 lacking a critical N-terminal ENTH domain, designated HIP1/ΔE, causes cell death. Vector (pcDNA3), full-length HIP1 (FLHIP1), HIP/ΔE (ΔE), and caspase-9 (casp-9) were transfected into 293T cells. Cell death was assayed by cellular morphology following transfection of the plasmid of interest. Western blot analysis was used to confirm expression of the various proteins. (c and d) TUNEL assays on transfected cells confirm that HIP1/ΔE–mediated cell death is apoptotic. Following transfection, cells were subjected to TUNEL assays with fluorescein-tagged dUTP and immunofluorescent labeling with HIP1 mAb. Confocal image analysis was carried out, and results for TUNEL labeling of full-length HIP1 and HIP1/ΔE –transfected cells are shown in c and d respectively, as TUNEL-positive cells (green), HIP1-immunofluorescent cells (red), and merged images. Bar graphs in c and d show the percentage of transfected cells (i.e., those staining red) that are also TUNEL-positive (green).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts